Vaxart, Inc.: Form 10-Q for the period ended Mar 31, 2014
Filed with the SEC on May 12, 2014 and accepted by EDGAR at May 12, 2014, 17:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-01-01 to 2014-03-31 | $29.5m | us-gaap:Revenues |
| Revenue | 9 months2013-07-01 to 2014-03-31 | $60.3m | us-gaap:Revenues |
| Cost of revenue | 9 months2013-07-01 to 2014-03-31 | $41.4m | us-gaap:CostOfServices |
| Research and development | 3 months2014-01-01 to 2014-03-31 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2013-07-01 to 2014-03-31 | $11.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-01-01 to 2014-03-31 | $3.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2013-07-01 to 2014-03-31 | −$1.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months2013-07-01 to 2014-03-31 | −$100.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-01-01 to 2014-03-31 | $3.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2013-07-01 to 2014-03-31 | −$800.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-01-01 to 2014-03-31 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2013-07-01 to 2014-03-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-01-01 to 2014-03-31 | $0.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2013-07-01 to 2014-03-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-01-01 to 2014-03-31 | 34,260,715 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2013-07-01 to 2014-03-31 | 30,127,156 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2013-07-01 to 2014-03-31 | −$13.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2013-07-01 to 2014-03-31 | $200.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-03-31 | $80.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-03-31 | $117.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-03-31 | $120.5m | us-gaap:Assets |
| Current liabilities | At period end2014-03-31 | $24.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-03-31 | $24.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-03-31 | $96.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-14-008749. Last ingested by Listed: Nov 5, 2026, 18:48 ET. Listed shows no prices and gives no investment advice.